Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04313881
Recruitment Status : Active, not recruiting
First Posted : March 18, 2020
Last Update Posted : December 9, 2022
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Biological: Magrolimab Drug: Azacitidine Biological: Placebo Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 520 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Actual Study Start Date : September 9, 2020
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026

Resource links provided by the National Library of Medicine

Drug Information available for: Azacitidine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Magrolimab + Azacitidine

Participants will receive the following magrolimab and azacitidine dosing regimens:

Magrolimab:

Magrolimab Priming Dose:

  • 1 mg/kg on Days 1 and 4
  • 15 mg/kg on Day 8
  • 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)

Magrolimab Maintenance Dose:

  • 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter

Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle

 Biological: Magrolimab
Administered intravenously
Other Names:
  • Hu5F9-G4
  • GS-4721

Drug: Azacitidine
Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
Placebo Comparator: Control Arm (Placebo + Azacitidine)

Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitadine:

Placebo Priming Dose:

  • 1 mg/kg on Days 1 and 4
  • 15 mg/kg on Day 8
  • 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)

Placebo Maintenance Dose:

  • 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter

Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle

 Drug: Azacitidine
Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling

Biological: Placebo
Placebo to match magrolimab administered intravenously


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of Participants with Complete Remission (CR) [ Time Frame: Up to 24 months ]
    The CR rate is the proportion of participants who reach morphologic CR based on Investigator-assessed International Working Group (IWG) 2006 Myelodysplastic Syndrome (MDS) criteria prior to initiation of any new MDS therapy including stem cell therapy (SCT).

  2. Overall Survival (OS) [ Time Frame: Up to 5 years ]
    OS is defined as the length measured from randomization to the date of death from any cause.


Secondary Outcome Measures :
  1. Duration of CR [ Time Frame: Up to 5 years ]
    The duration of CR is measured from the time measurement criteria are first met for CR to the first date of relapse or death, whichever occurs earlier. Those who are not observed to relapse or die will be censored at their last response assessment date with evidence of no relapse. Participants who achieve a CR and then proceed to an allogeneic SCT will continue to be followed for the response assessment post transplant, will be included in the analysis of duration of CR, and will not be censored at the time of transplant.

  2. Objective Response Rate (ORR) [ Time Frame: Up to 5 years ]
    ORR is the proportion of participants who reach objective response including CR, partial response (PR), marrow CR, or hematologic improvement per IWG 2006 MDS criteria prior to initiation of any new anticancer therapy for MDS, including SCT.

  3. Duration of Response (DOR) [ Time Frame: Up to 5 years ]
    DOR is measured from the time measurement criteria are first met for objective response to the first date of relapse, disease progression or death, whichever occurs earlier. Those who are not observed to relapse, disease progress or die will be censored at their last response assessment date with evidence of no relapse/no disease progression. Participants who achieve a response and then proceed to an allogeneic SCT will continue to be followed for the DOR post transplant, will be included in the analysis of DOR, and will not be censored at the time of transplant.

  4. Red Blood Cell (RBC) Transfusion Independence Rate [ Time Frame: Up to 5 years ]
    The RBC transfusion independence rate is the proportion of participants who have a 56-day or longer period with no RBC transfusions at any time between randomization and initiation of any new anticancer therapy, including SCT, among all participants who are RBC transfusion-dependent at baseline.

  5. Progression Free Survival (PFS) [ Time Frame: Up to 5 years ]
    The length of PFS is defined as the time from randomization to the date of documented disease progression (including treatment failure by IWG criteria or relapse after PR/CR), or death from any cause, whichever occurs first. Those who are not observed to have one of these events will be censored at their last response assessment date with evidence of no disease progression/relapse.

  6. Event Free Survival (EFS) [ Time Frame: Up to 5 years ]
    The length of EFS is defined as the time from randomization to transformation to acute myeloid leukemia (AML) or death from any cause, whichever occurs first. Participants who are not observed to have one of these events during the study will be censored at their last response assessment date with evidence of no transformation to AML.

  7. Minimal Residual Disease (MRD)-negative Response Rate [ Time Frame: Up to 5 years ]
    The MRD-negative response rate is defined as the proportion of participants who achieve a morphologic CR or marrow CR based on Investigator-assessed IWG criteria and reach MRD-negative disease status prior to initiation of any new anticancer therapy, including SCT. MRD-negative disease status will be assessed using a multiparameter flow cytometry-based assay performed by a central laboratory.

  8. Time to Transformation to AML [ Time Frame: Up to 5 years ]
    Time to transformation to AML is defined as the time from randomization to the collection date of bone marrow sample leading to documented AML diagnosis. Participants who are not observed to have transformation to AML will be censored at their last response assessment date with evidence of no AML diagnosis.

  9. Percentage of Participants Experiencing Treatment-Emergent Adverse Events [ Time Frame: Up to 5 years ]
  10. Serum Concentration of Magrolimab [ Time Frame: Up to 12 hours before administration of any treatment at Days 1, 8, 15, 22 of Cycle1; at Day 1 of Cycles 2, 3, 5, 7, 9, and 13, and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days ]
    Pretreatment assessments for the initial dose may be collected up to 72 hours before administration of study treatment; thereafter, pretreatment assessments are to be collected within 24 hours prior to study treatment administration.

  11. Anti-magrolimab Antibody Positivity Occurrence Rate [ Time Frame: Up to 72 hours before administration of any treatment at Day 1, Cycle 1; within 24 hours prior to any study drug administration at Day 1 of Cycles 2, 3, 5, 7, 10, and 13 and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days ]
  12. Functional Assessment of Cancer Therapy-Anemia (FACT-Anemia) Response Rate [ Time Frame: Up to 5 years ]

    The FACT-Anemia response rate is defined as the proportion of participants who showed clinically meaningful improvement in health-related quality of life (HRQoL) based on the score from the FACT-Anemia instrument prior to initiation of any new anticancer therapy for MDS, including SCT.

    The FACT-Anemia instrument consists of 5 subscales, including physical well-being, emotional well-being, functional well-being, social well-being, and anemia symptoms. Each subscale measures items on a 5-point Likert scale from 0 to 4, where 0 = not at all and 4 = very much.



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk.
  • Adequate performance status and hematological, liver, and kidney function

Key Exclusion Criteria:

  • Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor
  • Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents
  • Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R
  • Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year
  • Contraindications to azacitidine
  • Clinical suspicion of active central nervous system (CNS) involvement by MDS
  • Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history
  • Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening
  • Pregnancy or active breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04313881


Locations
Show Show 169 study locations
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT04313881    
Other Study ID Numbers: 5F9009
2020-004287-26 ( EudraCT Number )
First Posted: March 18, 2020    Key Record Dates
Last Update Posted: December 9, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Preleukemia
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
 Azacitidine
Magrolimab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Antineoplastic Agents, Immunological